<DOC>
	<DOC>NCT02207335</DOC>
	<brief_summary>Gemcitabine plus carboplatin in recurrent or metastatic breast cancer is a recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. gemcitabine in combination with capecitabine is also effective in Metastatic Breast Cancer (MBC) in some clinical study with small sample.</brief_summary>
	<brief_title>Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer</brief_title>
	<detailed_description>A multicenter randomized phase â…¢ clinical trial of gemcitabine in combination with capecitabine versus gemcitabine plus carboplatin as first-line treatment in triple-negative recurrent or metastatic breast cancer.The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Female 1870 years old ECOG 01 Expected lifetime more than 12 weeks Pregnancy Brain Metastasis, Severe Infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>